Jump to navigation
9 avril 2012
5 avril 2012
Gilles Saint-Paul
n° 12-285, 4 avril 2012
Marc Ivaldi
4 avril 2012
Emmanuelle Auriol
3 avril 2012
2 avril 2012
Ernst R. Berndt et Pierre Dubois
n° 12-283, mars 2012
Cross-country variability in regulatory frameworks, industrial policy, physician/pharmacy autonomy, brand/generic distinctions, and in the practice of medicine contributes to ambiguous interpretations of pharmaceutical cost comparisons. Here we report cross-country comparisons that: (i) focus on 11...
Patrick Fève et Ahmat Jidoud
n° 12-287, mars 2012
This paper investigates the reliability of SVARs to identify the dynamic effects of news shocks. We show analytically that the dynamics implied by SVARs, using both long–run and short–run restrictions, are biased. However, the bias vanishes as long as news shocks account for most of the variability...
n° 12-286, mars 2012
This paper assesses SVARs as relevant tools at identifying the aggregate effects of news shocks. When the econometrician and private agents’ information sets are not aligned, the dynamic responses identified from SVARs are biased. However, the bias vanishes when news shocks account for the bulk of...
Matthew Adler, James K. Hammitt et Nicolas Treich
n° 12-292, mars 2012
We examine how different welfarist frameworks evaluate the social value of mortality riskreduction. These frameworks include classical, distributively unweighted cost-benefit analysis—i.e., the “value per statistical life” (VSL) approach—and three benchmark social welfare functions (SWF): a...
